Chiasma Inc (NASDAQ:CHMA) Director Roni Mamluk sold 10,000 shares of the firm’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $4.94, for a total transaction of $49,400.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at $49,400. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Roni Mamluk also recently made the following trade(s):
- On Friday, September 20th, Roni Mamluk sold 50,000 shares of Chiasma stock. The shares were sold at an average price of $5.59, for a total transaction of $279,500.00.
NASDAQ:CHMA opened at $5.09 on Friday. Chiasma Inc has a 1-year low of $2.11 and a 1-year high of $9.25. The firm has a fifty day simple moving average of $5.09 and a 200 day simple moving average of $6.00.
A number of hedge funds have recently added to or reduced their stakes in CHMA. Strs Ohio bought a new position in Chiasma during the second quarter worth $560,000. Quantitative Systematic Strategies LLC bought a new position in Chiasma during the second quarter worth $100,000. Altshuler Shaham Ltd boosted its position in Chiasma by 143.2% during the second quarter. Altshuler Shaham Ltd now owns 101,953 shares of the biotechnology company’s stock worth $762,000 after purchasing an additional 60,026 shares during the period. Wells Fargo & Company MN bought a new position in Chiasma during the second quarter worth $237,000. Finally, JPMorgan Chase & Co. boosted its position in Chiasma by 242.8% during the second quarter. JPMorgan Chase & Co. now owns 73,139 shares of the biotechnology company’s stock worth $545,000 after purchasing an additional 51,806 shares during the period. 52.97% of the stock is owned by hedge funds and other institutional investors.
CHMA has been the subject of several analyst reports. ValuEngine cut shares of Chiasma from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Brookline Capital Management reissued a “buy” rating on shares of Chiasma in a research note on Wednesday, July 24th. Piper Jaffray Companies initiated coverage on shares of Chiasma in a research note on Wednesday, July 31st. They issued an “overweight” rating and a $11.00 target price for the company. Cantor Fitzgerald set a $18.00 target price on shares of Chiasma and gave the company a “buy” rating in a research note on Friday, September 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Chiasma in a research note on Tuesday, July 23rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $12.30.
Chiasma Company Profile
Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.
Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.